20 May
2021

AbbVie faces new patent abuse challenge in latest Humira suit

The latest in a series of high-profile adalimumab disputes could test innovative legal defences against patent thicketing and may have further procedural and tactical ramifications for biosimilar litigation.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth